Pharmacokinetic/pharmacodynamic modeling for dose selection for the first‐in‐human trial of the activated Factor XII inhibitor garadacimab (CSL312)

• Asıl Yazarlar: Dipti Pawaskar (Yazar), Xi Chen (Yazar), Fiona Glassman (Yazar), Frauke May (Yazar), Anthony Roberts (Yazar), Mark Biondo (Yazar), Andrew McKenzie (Yazar), Marc W. Nolte (Yazar), William J. Jusko (Yazar), Michael Tortorici (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Wiley, 2022-03-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Abstract Factor XII (FXII) is a serine protease involved in multiple cascades, including the kallikrein-kinin system. It may play a role in diseases in which the downstream cascades are dysregulated, such as hereditary angioedema. Garadacimab (CSL312) is a first‐in‐class, fully human, monoclonal ant...